Blood
Articles in this Issue
Treatment characteristics of 560 unfit patients with AML aged above 65 years: A single center analysis
Abstract Introduction: Patients with AML are suffering from low cell counts resulting in higher risks for infections and bleeding. Patients...
Impact of acute kidney injury on mortality and resource utilization in hospitalized patients with multiple myeloma
Abstract Background Acute kidney injury (AKI) is a frequent and serious complication among patients with multiple myeloma (MM), occurring du...
AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq
Abstract Background Recent advances in next-generation sequencing (NGS) and transcriptomic profiling have refined the mo...
Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study
Abstract Background The advent of novel targeted and immunotherapeutic approaches, particularly Bruton's tyrosine kinase inhibitors (BTKis),...
Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies
Abstract Introduction: The role of autologous stem cell transplantation (ASCT) in older patients (pts) with multiple myeloma (MM) is being re...
IL1RAP, but not CD366 (TIM3), may aid the detection of abnormal myeloblasts in myeloid neoplasia by flow cytometry
Abstract Identification of an abnormal immunophenotype by flow cytometric analysis is important for the diagnosis of acute myeloid leukemia...
Trends and regional variations in survivorship care plan delivery among hematologic cancer survivors in the United States
Abstract Background: Hematologic cancer survivors face complex long-term health challenges that require coordinated follow-up care. Survivor...
Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL
Abstract Introduction: Dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cell therapy has demonstrated high o...
Impact of early dose escalation and treatment duration on hematologic response in ropeginterferon alfa-2b treatment for polycythemia vera
Abstract Introduction As recommended by NCCN Guidelines, Ropeginterferon Alfa-2b (Ropeg) is a therapy of choice for both low and high-risk P...
Diagnostic value of pathogen metagenomic next-generation sequencing (mNGS) for early bloodstream infections in pediatric allogeneic hematopoietic stem cell transplantation recipients
Abstract Background: Early bloodstream infection (EBSI) remains a principal determinant of morbidity and mortality after paediatric allogene...
6pLOH as a marker of immune-mediated bone marrow failure: Insights from a large single center experience
Abstract Copy-neutral loss of heterozygosity on chromosome 6p (6pLOH) is a recurrent acquired event in aplastic anemia (AA), detectable by S...
A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1
Abstract Introduction Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) for which the only approved therapies are JAK inhibitors whi...
MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg
Abstract Background: The CLL2-BAG phase 2 trial was among the first to evaluate venetoclax (Ven) plus obinutuzumab (Obi). Another novelty in...
Disruption of IL-10 receptor signaling promotes hematopoietic stem cell exhaustion and clonal expansion of JAK2V617F mutant cells during inflammatory stress
Abstract The ability of hematopoietic stem cells (HSCs) to return to quiescence after inflammatory activation is critical for long-term stem...
Estimating and forecasting the incidence, prevalence, and counts of treatment-eligible patients with diffuse large-B cell lymphoma and Mantle Cell Lymphoma in the US
Abstract Introduction: Non-Hodgkin lymphoma (NHL) is the most common hematologic cancer in the US, with an estimated 80,350 new cases in 202...
Overcoming maturation deficits in iPSC-NK cells through programmable T-bet induction
Abstract Introduction Induced pluripotent stem cells (iPSC) represent a promising platform for generating Natural Killer...
Evaluation of a newly formulated intranasal desmopressin versus intranasal and subcutaneous desmopressin in individuals with type 1 von Willebrand disease and mild Hemophilia A
Abstract Introduction: Desmopressin (DDAVP) is a cost-effective, safe, and efficacious treatment for bleeding in persons with von Willebrand...
Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis
Abstract Introduction The curative potential of hematopoietic stem cell transplantation (HSCT) in pediatric patients with relapsed or refrac...
Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification
Abstract Background: Extramedullary disease (EMD) in acute myeloid leukemia (AML) involves leukemic infiltration outside the bone marrow and...
Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.
Abstract INTRODUCTION: Autologous stem cell transplantation (ASCT) is the standard of care for younger patients with newly diagnosed multipl...
Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma
Abstract Background: NF-κB transcription factors are major drivers of multiple myeloma (MM) aetiopathogenesis, malignant...
Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia
Abstract Background and significance: Venetoclax (VEN)-based lower-intensity therapies are the current standard for older/unfit patients (pt...
Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study
Abstract Introduction: Relapse or refractory acute myeloid leukemia (R/R AML) is a highly heterogeneous disease with poo...
Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report
Abstract Background Birelentinib (DZD8586) is a LYN/BTK dual inhibitor designed to block both BTK-dependent and BTK-independent BCR signallin...
PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course
Abstract Background: Despite recent therapeutic advances in AS cHL, PET-adaptive chemotherapy-based regimens remain a first-line treatment o...